Endocrine Board Review 2026, 18th Edition (book)
Availability
On-Demand
2 Courses
Expires on Dec 31, 2027
Cost
Member: $199.00
Non-Member: $259.00
In-Training Member: $169.00
Resident Member: $169.00
Resident Non-Member: $259.00
Credit Offered
55 AMA PRA Category 1 Credits
55 ABIM-MOC Points
55 Participation Credits
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

Endocrine Board Review (EBR) is a board examination preparation course designed both for endocrine fellows who have completed or are nearing completion of their fellowship and are preparing to sit the board certification exam, and for practicing endocrinologists in search of a comprehensive self-assessment of endocrinology, either to prepare for recertification or to update their practice. EBR 2026 consists of 227 case-based, American Board of Internal Medicine (ABIM)-style multiple-choice questions, presented in a mock exam format. Each section follows the ABIM’s Endocrinology, Diabetes, and Metabolism Certification Examination blueprint, covering the breadth and depth of the certification and recertification examinations. Each case is discussed comprehensively with detailed answer explanations and references. A customized score report is provided to all participants. The book provides access to the following components:

  • Endocrine Board Review 18th Edition—printed self-study book containing all 227 case-based questions and complete answer rationale.
  •  Interactive Practice Exam— Access 227 questions to evaluate your knowledge in key topical areas to enhance your ability to make appropriate diagnoses. This practice exam allows the learner to create their own test based on topical area, with options to adjust length of time, and measure confidence level in responses. You can submit questions for our faculty to address during the live Study Sessions based on specific case questions.
    • Learning Mode: Answer 227 questions and receive immediate feedback and view the detailed answer rationale. This mode must be completed with a passing score of 70% in order to earn CME and MOC. You will be given unlimited attempts to obtain this score.
    • Mock Exam Mode: Perfect for simulating an exam. Retake this mock exam as often as you like and each time the questions will be re-organized. Feedback will be provided after completion of the exam.
      • Build your own exam: Within Mock Exam Mode, you have the option to create your own exams by choosing the topic(s) to be included and even set a timer.
This activity is intended for endocrine fellows planning for initial certification, practicing endocrinologists preparing for an MOC recertification exam, or physicians seeking an in-depth review of endocrinology.

Upon completion of this educational activity, learners will be able to:

  • Demonstrate enhanced medical knowledge and clinical skills across all major areas of endocrinology.
  • Apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders.
  • Successfully complete the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates the Endocrine Board Review 2026 18th Edition for a maximum of 55 AMA PRA Category 1 Credits and 55 points in the ABIM Maintenance of Certification (MOC) program. Successful completion of this CME activity includes participation in the activity evaluation.  After completing the activity evaluation, participants will be able to save or print a CME certificate. The CME activity provider is responsible for submitting participant completion information to the ACCME to grant ABIM MOC points.  

CME credits and/or MOC points for the Endocrine Board Review 2026 18th Edition activity related to this material must be claimed by December 31, 2027. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in the Endocrine Board Review 2026 18th Edition for a maximum of 55 AMA PRA Category 1 Credits™ and designates the Endocrine Board Review 2026 Live Study Sessions for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in the Endocrine Board Review 2026 18th Edition course, which includes participation in the evaluation component, enables the participant to earn up to 55 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) prgram. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Irina Bancos, MD Adrenas, Corcept, Esteve, Recordati, Xeris (Advisory Board); Adaptyx, Astrazeneca, Camurus, Corcept, Crinetics, Diurnal, Esteve, Neurocrine, Recordati, Sparrow Pharmaceutics, Spruce (Consultant); European Journal of Endocrinology (Editor); Esteve, Recordati (Research Support); Dynamed (Reviewer); Elsevier (Writer).

Shagun Bindlish, MD Golden State Obesity Society (Founder and President), American Diabetes Association journal Clinical Diabetes, Obesity Medicine Association journal Pillars of Medicine (Associate Editor).

John D. Carmichael, MD American Association of Clinical Endocrinologists and Pituitary Society (Member); Novo Nordisk, Camurus, Xeris (Advisory Board); Crinetics, Novo Nordisk (Research Support).

Marcelo Correia, MD, MSc, PhD The Obesity Society (Member); Novartis, Eli Lilly, Novo Nordisk, Stead Family (Iowa), National Institutes of Health, PCORI (Research Support); Novo Nordisk (Advisory Board and Consultant); Genentech/Roche (Advisory Board).

Natalie Cusano, MD, MS Ascendis Pharma, Extend Biosciences (Consultant); Endocrine Practice (Editor); Ascendis Pharma, Takeda/Shire (Research Support); Alexion (Speaker).

Kaniksha Desai, MD Endocrine Practice (Editor); American Thyroid Association, American Association of Clinical Endocrinologists, Thyroid Disease State Network (Member); Medscape Podcast on Thyroid Diseases (Host).

Hans K. Ghayee, DO Corcept (Consultant); SDHB Pheo Para Coalition (Funding); University of Texas Southwestern Medical Center (Royalties). 

Sangeeta Kashyap, MD GI Dynamics (Consultant); Fractyl, Inc (Research Support). 

E. Michael Lewiecki, MD Ultragenyx, Angitia (Institutional Research Grants); Amgen, Radius, Kyowa Kirin, Angitia, Ascendis (Consultant); Amgen, Radius, Ascendis, Kyowa Kirin (Speaker).

Cecilia C. Low Wang, MD American Association of Clinical Endocrinology, American College of Diabetology, American Heart Association, Clinical Diabetes and Endocrinology Institute (Advisory Board); Clinical Diabetes and Endocrinology Institute, Medical Education Resources, Continuing Education Company (Speaker); Dexcom Inc, Virta Health (Research Funding); American Heart Association (Guidelines Committee); FDA Advisory Committee for Endocrinologic Metabolic Drugs (Committee Member).

Elizabeth McAninch, MD Acella Pharmaceuticals, AbbVie Inc (Consultant); Equilibrate Therapeutics, LLC (Cofounder).

Stephanie Page, MD, PhD Pharmajor International (Consultant).

The following faculty reported no relevant financial relationships: Dima L. Diab, MD; Margaret Flynn Lippincott, MD; Aniket Sidhaye, MD; and Catherine D. Zhang, MD.

The medical editor for this activity reported no relevant financial relationships: Abbie L. Young, MS, CGC, ELS(D)

Endocrine Society staff involved in developing content for this activity reported no relevant financial relationships.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
The activity is not supported by educational grant(s) or other funds from any commercial supporters.   

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By